Clinical Trial Update: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of MT-601 in relapsed/refractory lymphoma shows safety and preliminary efficacy signals in both non-Hodgkin lymphoma and Hodgkin lymphoma, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MT-601

Snippet

Sponsor: Marker Therapeutics, Inc. | Conditions: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory | Phase 1 | Status: RECRUITING